Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity.
about
Alcohol-induced disruption of endocrine signalingInhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.Effects of atorvastatin 10 mg/d on insulin resistance: A 12-week, open-label study in hyperlipidemic patients.Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?Statins and their increased risk of inducing diabetes.HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway.The PathLinker app: Connect the dots in protein interaction networks.Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway.Overexpression of Ha-ras selectively in adipose tissue of transgenic mice. Evidence for enhanced sensitivity to insulin.Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.Statins and modulation of oxidative stress.No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia.Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats.Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro.Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders.Methylglyoxal attenuates insulin signaling and downregulates the enzymes involved in cholesterol biosynthesis.Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress.
P2860
Q28305674-32C376EB-B6E5-461C-9385-DAC10D025237Q35028546-E4D50091-2F45-4C06-B0BD-B86DBCFE0D86Q37663572-2878CBDC-96BF-4F39-BA7C-B526D76F967DQ38268344-6BFA35AF-4CD1-44D2-87AD-05CFE97D076BQ38599323-6A80AE8D-FDE9-4AB3-A0B8-2B5EAF1203EEQ40992838-D37CF75E-E35F-429C-937D-A39BE94D6382Q41987791-EC0A1D2C-9EEB-406C-A16A-B5DE50CF01E8Q42514245-741E1A76-7952-4186-942F-80850A30F52CQ42517372-BB0561B7-A480-4AD0-9A53-51C61AA5D076Q42807654-A6C06DCF-0897-488E-8C6D-41FC6D146D87Q43215640-8B327130-11C1-4EE7-86CA-92736CC4B41FQ44611689-FF964227-0175-4599-84A9-81B2E78B8308Q45154726-CC71EFE7-5F2F-4571-8D85-B12F0C742F31Q46243045-4A467AC9-3D94-4F77-9A69-5644A790CAFDQ46449145-656EA71D-14AF-414C-9845-E65C49DA1DD4Q47779685-E9F556F9-102F-4BA1-8162-F0FAF749BB99Q53224987-F3952033-D9EB-4C63-9BF7-1D0355147ED5
P2860
Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Lovastatin disrupts early even ...... tin's anti-mitogenic activity.
@en
type
label
Lovastatin disrupts early even ...... tin's anti-mitogenic activity.
@en
prefLabel
Lovastatin disrupts early even ...... tin's anti-mitogenic activity.
@en
P2093
P356
P1476
Lovastatin disrupts early even ...... tin's anti-mitogenic activity.
@en
P2093
P304
P356
10.1006/BBRC.1994.2472
P577
1994-10-01T00:00:00Z